{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021721","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.705574+00:00","generated_at":"2026-05-16T21:53:17.761119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Abeona Q3 net loss narrows to $5.2M; ZEVASKYN first treatment delayed to Q4 2025","bullets":["Net loss of $5.2M ($0.10/sh) vs $30.3M ($0.63/sh) in Q3 2024; R&D expense fell to $4.2M, SG&A rose to $19.3M on commercial launch.","Cash $207.5M at Sep 30, expected to fund operations over two years without ZEVASKYN revenue.","First ZEVASKYN patient treatment shifted to Q4 2025 after sterility assay false positive; biopsy collection resumed Nov 2025.","Patient demand growing: 30 eligible patients identified at two QTCs; 12 product order forms received; three centers activated.","Major commercial payers covering ~60% of RDEB patients; CMS J-code effective Jan 1, 2026; ABO-503 accepted into FDA RDEA program."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021721","json":"https://secwatch.observer/filing/0001493152-25-021721.json","markdown":"https://secwatch.observer/filing/0001493152-25-021721.md","text":"https://secwatch.observer/filing/0001493152-25-021721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315225021721/0001493152-25-021721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315225021721/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:53:17.761119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}